Eli Lilly's ... comparison that masks true operational performance. What I find most compelling is the broad nature of the growth. While much attention focuses on Lilly's incretin franchise ...
Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...
They knew people who were taking Zepbound, Wegovy, Mounjaro, Ozempic. And so they piled in and the valuations, I mean, Eli Lilly is trading ... and that kind of masks for a while our understanding ...
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
This surge was largely driven by its blockbuster GLP-1 receptor agonists, Mounjaro and Zepbound, which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback